![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the agreement, Medicom has acquired the ownership of the pharmaceutical dossier of Zimed (bimatoprost), a preservative free eye drop solution, which is already registered in the UK and 5 EU countries with plans to commercialise the asset globally.
Lead Product(s): Bimatoprost
Therapeutic Area: Ophthalmology Product Name: Zimed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Famar
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition February 09, 2021